Table 3.
Laboratory results of patients with COVID-19.
| Variable | Patients of COVID-19 with pancreatitis | Patients of COVID-19 withelevated Pancreatic enzymes(N = 29) | Patients of COVID-19 without elevated enzymes (N = 23) | P | |||
|---|---|---|---|---|---|---|---|
| P1 | P2 | P3 | Overall | ||||
| Blood cytology(10 9 /L)Mean ± SD | |||||||
| Leukocytes (3.5–9.5) | 33.48 | 12.64 | 7.84 | 18.0 ± 13.6 | 11.0 ± 5.5 | 8.40 ± 3.6 | 0.09 |
| Neutrophils (1.8–6.3) | 32.55 | 11.89 | 7.23 | 17.2 ± 13.5 | 12.7 ± 15.3 | 7.30 ± 3.5 | 0.17 |
| Lymphocyte (1.1–3.2) | 0.4 | 0.44 | 0.47 | 0.44 ± 0.04 | 0.72 ± 0.6 | 0.70 ± 0.2 | 0.55 |
| Platelets (125–350) | 234 | 220 | 114 | 189.3 ± 65.6 | 201 ± 116.9 | 190.20 ± 77.3 | 0.92 |
| NLR | 81.4 | 27.0 | 15.4 | 41.3 ± 35.2 | 28.7 ± 40.5 | 12.40 ± 7.5 | 0.06 |
| PLR | 585 | 500 | 242.3 | 442.5 ± 178.3 | 437.8 ± 493.2 | 320.00 ± 182.0 | 0.53 |
| Inflammatory indicatorsMean ± SD | |||||||
| CRP (0–5 mg/L) | 122.5 | 160 | 43.8 | 108.8 ± 59.3 | 103.4 ± 53.5 | 95.3 ± 57.2 | 0.13 |
| PCT (<0.5 ng/ml) | 0.24 | 0.2 | 0.05 | 0.16 ± 0.1 | 0.81 ± 2.5 | 0.32 ± 0.55 | 0.66 |
| ESR (0–20 mm/h) | 37 | 115 | 65 | 72.3 ± 39.5 | 54.2 ± 22.0 | 62.3 ± 26.4 | 0.22 |
| IL-6 (0–7) | 13.7 | 12.8 | 9.2 | 11.9 ± 2.4 | 12.9 ± 8.3 | 10.10 ± 4.3 | 0.88 |
| Blood biochemistryMean ± SD | |||||||
| ALB (40–55 G/L) | 30.8 | 26.7 | 27 | 28.2 ± 2.3 | 30.9 ± 9.1 | 28.90 ± 4.8 | 0.59 |
| ALT (7–40 U/L) | 129 | 48 | 25 | 67.3 ± 54.6 | 66.00 ± 107.9 | 38.30 ± 40.2 | 0.49 |
| AST (13–35 U/L) | 65 | 35 | 32 | 44 ± 18.2 | 60.9 ± 50.3 | 41.70 ± 18.1 | 0.21 |
| γ-GT (7–45 U/L) | 159 | 112 | 50 | 107 ± 54.7 | 92.40 ± 84.4 | 89.70 ± 138.6 | 0.97 |
| ALP (50–135 U/L) | 108 | 122 | 44 | 91.3 ± 41.6 | 112.70 ± 56.0 | 104.3 ± 58.5 | 0.76 |
| TB (0–21 umol/L) | 12 | 24.6 | 9.8 | 15.5 ± 8.0 | 22.10 ± 18.7 | 13.20 ± 7.3 | 0.162 |
| Cr (41–81 umol/L) | 31.8 | 39 | 81.7 | 50.8 ± 27.0 | 145.40 ± 262.7 | 184.50 ± 276.5 | 0.68 |
| LDH (120–250 U/L) | 672 | 209 | 337 | 406 ± 239.1 | 697.10 ± 635.46 | 483.00 ± 213.6 | 0.24 |
| CK (40–200 U/L) | 123 | 258 | 35 | 138.7 ± 112.3 | 234.0690 ± 384.8 | 208 ± 185.1 | 0.86 |
| CK-MB (0–24 U/L) | 17 | 12 | 7 | 12 ± 5 | 19.60 ± 22.1 | 19.80 ± 15.0 | 0.79 |
| TnT (0–28 Pg/ml) | 127.8 | 7.7 | 5.2 | 46.9 ± 70.1 | 1418.9 ± 5599.1 | 76.00 ± 179.9 | 0.48 |
| Coagulation functionsMean ± SD | |||||||
| PT (10.5–13.5S) | 10.1 | 13.4 | 9.5 | 11 ± 21 | 13.70 ± 5.3 | 17.70 ± 19.3 | 0.47 |
| APTT (21–37S) | 19.1 | 27.3 | 17.5 | 21.3 ± 5.3 | 30.30 ± 7.8 | 34.30 ± 18.4 | 0.23 |
| INR (0.8–1.2) | 0.87 | 1.18 | 0.82 | 0.96 ± 0.2 | 1.20 ± 0.6 | 1.43 ± 1.6 | 0.63 |
| Fibrinogen (2–4 g/l) | 4 | 7.2 | 1.1 | 4.1 ± 3.1 | 4.30 ± 1.8 | 5.10 ± 2.1 | 0.3 |
NLR, rate of neutrophils and lymphatic; PLR, rate of platelets and lymphatic; CRP, C-reactive protein; PCT, procalcitonin; ESR, erythrocyte sedimentation rate; IL-6, interleukin 6; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TB, total bilirubin; γ-GT, γ-glutamyltranspeptidase; Cr, creatinine; LDH, dehydrogenase; CK, creatine kinase; CK-MB, creatine kinase-MB; TnT, troponin T; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio.